Adenosine is an agonist of the A1 receptor in the AV node, which inhibits adenylyl cyclase and reduces cAMP levels. This leads to hyperpolarisation by increasing potassium outflow, effectively preventing supraventricular tachycardia from continuing. It is important to note that adenosine is not an alpha receptor antagonist, beta-2 receptor agonist, or beta receptor antagonist.

Adenosine is commonly used to stop supraventricular tachycardias. Its effects are boosted by dipyridamole, an antiplatelet agent, but blocked by theophyllines. However, asthmatics should avoid it due to the risk of bronchospasm. Adenosine works by causing a temporary heart block in the AV node. It activates the A1 receptor in the atrioventricular node, which inhibits adenylyl cyclase, reducing cAMP and causing hyperpolarization by increasing outward potassium flux. Adenosine has a very short half-life of about 8-10 seconds and should be infused through a large-caliber cannula.

Adenosine can cause chest pain, bronchospasm, and transient flushing. It can also enhance conduction down accessory pathways, leading to an increased ventricular rate in conditions such as WPW syndrome.

The resting potential of cardiac myocytes is maintained by potassium, while depolarization is initiated by a sudden influx of sodium ions and repolarization is caused by the outflow of potassium. The extended duration of a cardiac action potential, in contrast to skeletal muscle, is due to a gradual influx of calcium.

Understanding the Cardiac Action Potential and Conduction Velocity

The cardiac action potential is a series of electrical events that occur in the heart during each heartbeat. It is responsible for the contraction of the heart muscle and the pumping of blood throughout the body. The action potential is divided into five phases, each with a specific mechanism. The first phase is rapid depolarization, which is caused by the influx of sodium ions. The second phase is early repolarization, which is caused by the efflux of potassium ions. The third phase is the plateau phase, which is caused by the slow influx of calcium ions. The fourth phase is final repolarization, which is caused by the efflux of potassium ions. The final phase is the restoration of ionic concentrations, which is achieved by the Na+/K+ ATPase pump.

Conduction velocity is the speed at which the electrical signal travels through the heart. The speed varies depending on the location of the signal. Atrial conduction spreads along ordinary atrial myocardial fibers at a speed of 1 m/sec. AV node conduction is much slower, at 0.05 m/sec. Ventricular conduction is the fastest in the heart, achieved by the large diameter of the Purkinje fibers, which can achieve velocities of 2-4 m/sec. This allows for a rapid and coordinated contraction of the ventricles, which is essential for the proper functioning of the heart. Understanding the cardiac action potential and conduction velocity is crucial for diagnosing and treating heart conditions.

Individuals with Marfan syndrome may exhibit various connective tissue disorders, including bilateral inguinal hernia. They are particularly susceptible to aortic dissection, as demonstrated in this instance.

Aortic dissection is a serious condition that can cause chest pain. It occurs when there is a tear in the inner layer of the aorta’s wall. Hypertension is the most significant risk factor, but it can also be associated with trauma, bicuspid aortic valve, and certain genetic disorders. Symptoms of aortic dissection include severe and sharp chest or back pain, weak or absent pulses, hypertension, and aortic regurgitation. Specific arteries’ involvement can cause other symptoms such as angina, paraplegia, or limb ischemia. The Stanford classification divides aortic dissection into type A, which affects the ascending aorta, and type B, which affects the descending aorta. The DeBakey classification further divides type A into type I, which extends to the aortic arch and beyond, and type II, which is confined to the ascending aorta. Type III originates in the descending aorta and rarely extends proximally.

Warfarin causes an increase in prothrombin-time (PT) and international normalised ratio (INR) by inhibiting vitamin K-dependent clotting factors. An increase in PT will cause an increase in INR, and a decrease in PT and INR is a prothrombotic state.

Understanding Warfarin: Mechanism of Action, Indications, Monitoring, Factors, and Side-Effects

Warfarin is an oral anticoagulant that has been widely used for many years to manage venous thromboembolism and reduce stroke risk in patients with atrial fibrillation. However, it has been largely replaced by direct oral anticoagulants (DOACs) due to their ease of use and lack of need for monitoring. Warfarin works by inhibiting epoxide reductase, which prevents the reduction of vitamin K to its active hydroquinone form. This, in turn, affects the carboxylation of clotting factor II, VII, IX, and X, as well as protein C.

Warfarin is indicated for patients with mechanical heart valves, with the target INR depending on the valve type and location. Mitral valves generally require a higher INR than aortic valves. It is also used as a second-line treatment after DOACs for venous thromboembolism and atrial fibrillation, with target INRs of 2.5 and 3.5 for recurrent cases. Patients taking warfarin are monitored using the INR, which may take several days to achieve a stable level. Loading regimes and computer software are often used to adjust the dose.

Factors that may potentiate warfarin include liver disease, P450 enzyme inhibitors, cranberry juice, drugs that displace warfarin from plasma albumin, and NSAIDs that inhibit platelet function. Warfarin may cause side-effects such as haemorrhage, teratogenic effects, skin necrosis, temporary procoagulant state, thrombosis, and purple toes.

In summary, understanding the mechanism of action, indications, monitoring, factors, and side-effects of warfarin is crucial for its safe and effective use in patients. While it has been largely replaced by DOACs, warfarin remains an important treatment option for certain patients.

The patient’s symptoms suggest that he may have experienced an ST elevation myocardial infarction in the inferior wall of his heart. There are various complications that can arise after a heart attack, and the timing of these complications can vary.

1. Ventricular arrhythmia is a common cause of death after a heart attack, but it typically occurs within the first 24 hours.
2. Ventricular septal defect, which is caused by a rupture in the interventricular septum, is most likely to occur 3-5 days after a heart attack.
3. This complication is autoimmune-mediated and usually occurs several weeks after a heart attack.
4. Cardiac tamponade can occur when bleeding into the pericardial sac impairs the heart’s contractile function. This complication is most likely to occur 5-14 days after a heart attack.
5. Mural thrombus, which can result from the formation of a true ventricular aneurysm, is most likely to occur at least two weeks after a heart attack. Ventricular pseudoaneurysm, on the other hand, can occur 3-14 days after a heart attack.

Understanding Cardiac Tamponade

Cardiac tamponade is a medical condition where there is an accumulation of pericardial fluid under pressure. This condition is characterized by several classical features, including hypotension, raised JVP, and muffled heart sounds, which are collectively known as Beck’s triad. Other symptoms of cardiac tamponade include dyspnea, tachycardia, an absent Y descent on the JVP, pulsus paradoxus, and Kussmaul’s sign. An ECG can also show electrical alternans.

It is important to differentiate cardiac tamponade from constrictive pericarditis, which has different characteristic features such as an absent Y descent, X + Y present JVP, and the absence of pulsus paradoxus. Constrictive pericarditis is also characterized by pericardial calcification on CXR.

The management of cardiac tamponade involves urgent pericardiocentesis. It is crucial to recognize the symptoms of cardiac tamponade and seek medical attention immediately to prevent further complications.

The patient has a bradycardia with a narrow QRS complex, ruling out bundle branch blocks. It is not a first-degree heart block or a Wenckebach heart block. The correct diagnosis is a 2:1 heart block with 2 P waves to each QRS complex.

Understanding Heart Blocks: Types and Features

Heart blocks are a type of cardiac conduction disorder that can lead to serious complications such as syncope and heart failure. There are three types of heart blocks: first degree, second degree, and third degree (complete) heart block.

First degree heart block is characterized by a prolonged PR interval of more than 0.2 seconds. Second degree heart block can be further divided into two types: type 1 (Mobitz I, Wenckebach) and type 2 (Mobitz II). Type 1 is characterized by a progressive prolongation of the PR interval until a dropped beat occurs, while type 2 has a constant PR interval but the P wave is often not followed by a QRS complex.

Third degree (complete) heart block is the most severe type of heart block, where there is no association between the P waves and QRS complexes. This can lead to a regular bradycardia with a heart rate of 30-50 bpm, wide pulse pressure, and cannon waves in the neck JVP. Additionally, variable intensity of S1 can be observed.

It is important to recognize the features of heart blocks and differentiate between the types in order to provide appropriate management and prevent complications. Regular monitoring and follow-up with a healthcare provider is recommended for individuals with heart blocks.

Thiazide-like drugs such as indapamide work by blocking the Na+-Cl− symporter at the beginning of the distal convoluted tubule, which inhibits sodium reabsorption. Loop diuretics, on the other hand, inhibit the Na+ K+ 2Cl- cotransporters in the thick ascending loop of Henle. Amiloride, a potassium-sparing diuretic, inhibits the epithelial sodium channels in the cortical collecting ducts, while spironolactone, another potassium-sparing diuretic, blocks the action of aldosterone on aldosterone receptors and inhibits the Na+/K+ exchanger in the cortical collecting ducts.

Thiazide diuretics are medications that work by blocking the thiazide-sensitive Na+-Cl− symporter, which inhibits sodium reabsorption at the beginning of the distal convoluted tubule (DCT). This results in the loss of potassium as more sodium reaches the collecting ducts. While thiazide diuretics are useful in treating mild heart failure, loop diuretics are more effective in reducing overload. Bendroflumethiazide was previously used to manage hypertension, but recent NICE guidelines recommend other thiazide-like diuretics such as indapamide and chlorthalidone.

Common side effects of thiazide diuretics include dehydration, postural hypotension, and electrolyte imbalances such as hyponatremia, hypokalemia, and hypercalcemia. Other potential adverse effects include gout, impaired glucose tolerance, and impotence. Rare side effects may include thrombocytopenia, agranulocytosis, photosensitivity rash, and pancreatitis.

It is worth noting that while thiazide diuretics may cause hypercalcemia, they can also reduce the incidence of renal stones by decreasing urinary calcium excretion. According to current NICE guidelines, the management of hypertension involves the use of thiazide-like diuretics, along with other medications and lifestyle changes, to achieve optimal blood pressure control and reduce the risk of cardiovascular disease.

When a young patient presents with symptoms of syncope and chest discomfort, along with a family history of hypertrophic cardiomyopathy (HOCM), it is important to consider the possibility of this condition. Asymmetric septal hypertrophy and systolic anterior movement (SAM) of the anterior leaflet of the mitral valve on echocardiogram or cMR are supportive of HOCM. This condition is caused by a genetic defect in the beta-myosin heavy chain protein gene. While Brugada syndrome may also be a consideration, it is not listed as a possible answer due to its underlying mechanism of sodium channelopathy.

Hypertrophic obstructive cardiomyopathy (HOCM) is a genetic disorder that affects muscle tissue and is inherited in an autosomal dominant manner. It is caused by mutations in genes that encode contractile proteins, with the most common defects involving the β-myosin heavy chain protein or myosin-binding protein C. HOCM is characterized by left ventricle hypertrophy, which leads to decreased compliance and cardiac output, resulting in predominantly diastolic dysfunction. Biopsy findings show myofibrillar hypertrophy with disorganized myocytes and fibrosis. HOCM is often asymptomatic, but exertional dyspnea, angina, syncope, and sudden death can occur. Jerky pulse, systolic murmurs, and double apex beat are also common features. HOCM is associated with Friedreich’s ataxia and Wolff-Parkinson White. ECG findings include left ventricular hypertrophy, non-specific ST segment and T-wave abnormalities, and deep Q waves. Atrial fibrillation may occasionally be seen.

Furosemide is a loop diuretic that works by inhibiting the Na-K-Cl cotransporter in the thick ascending limb of the loop of Henle. It is commonly used to treat fluid retention in patients with heart failure. Other diuretic agents work on different parts of the nephron, such as carbonic anhydrase inhibitors in the proximal and distal tubules, thiazide diuretics in the distal convoluted tubule, and potassium-sparing diuretics like amiloride and spironolactone in the cortical collecting ducts. Understanding the mechanism of action of diuretics can help clinicians choose the most appropriate medication for their patients.

Loop Diuretics: Mechanism of Action and Clinical Applications

Loop diuretics, such as furosemide and bumetanide, are medications that inhibit the Na-K-Cl cotransporter (NKCC) in the thick ascending limb of the loop of Henle. By doing so, they reduce the absorption of NaCl, resulting in increased urine output. Loop diuretics act on NKCC2, which is more prevalent in the kidneys. These medications work on the apical membrane and must first be filtered into the tubules by the glomerulus before they can have an effect. Patients with poor renal function may require higher doses to ensure sufficient concentration in the tubules.

Loop diuretics are commonly used in the treatment of heart failure, both acutely (usually intravenously) and chronically (usually orally). They are also indicated for resistant hypertension, particularly in patients with renal impairment. However, loop diuretics can cause adverse effects such as hypotension, hyponatremia, hypokalemia, hypomagnesemia, hypochloremic alkalosis, ototoxicity, hypocalcemia, renal impairment, hyperglycemia (less common than with thiazides), and gout. Therefore, careful monitoring of electrolyte levels and renal function is necessary when using loop diuretics.

Orthopnoea is a useful indicator to distinguish between heart failure and COPD.

The Framingham diagnostic criteria for heart failure include major criteria such as acute pulmonary oedema and cardiomegaly, as well as minor criteria like ankle oedema and dyspnoea on exertion. Other minor criteria include hepatomegaly, nocturnal cough, pleural effusion, tachycardia (>120 /min), neck vein distension, and a third heart sound.

In this case, the patient exhibits orthopnoea (needing an extra pillow to alleviate breathlessness), rales (crackles heard during inhalation), and dyspnoea on exertion, all of which are indicative of heart failure.

While COPD can present with similar symptoms such as coughing, fatigue, shortness of breath, and desaturation, the presence of orthopnoea helps to differentiate between the two conditions.

Pulmonary fibrosis, on the other hand, does not typically present with orthopnoea.

Features of Chronic Heart Failure

Chronic heart failure is a condition that affects the heart’s ability to pump blood effectively. It is characterized by several features that can help in its diagnosis. Dyspnoea, or shortness of breath, is a common symptom of chronic heart failure. Patients may also experience coughing, which can be worse at night and accompanied by pink or frothy sputum. Orthopnoea, or difficulty breathing while lying down, and paroxysmal nocturnal dyspnoea, or sudden shortness of breath at night, are also common symptoms.

Another feature of chronic heart failure is the presence of a wheeze, known as a cardiac wheeze. Patients may also experience weight loss, known as cardiac cachexia, which occurs in up to 15% of patients. However, this may be hidden by weight gained due to oedema. On examination, bibasal crackles may be heard, and signs of right-sided heart failure, such as a raised JVP, ankle oedema, and hepatomegaly, may be present.

In summary, chronic heart failure is a condition that can be identified by several features, including dyspnoea, coughing, orthopnoea, paroxysmal nocturnal dyspnoea, wheezing, weight loss, bibasal crackles, and signs of right-sided heart failure. Early recognition and management of these symptoms can help improve outcomes for patients with chronic heart failure.

To assess lower leg pulses, it is recommended to start from the most distal point and move towards the proximal area. This helps to identify the location of any occlusion. The first pulse to be checked is the dorsalis pedis pulse, which is located on the dorsum of the foot in the first metatarsal space, lateral to the extensor hallucis longus tendon. Palpating behind the knee or in the fourth metatarsal space is incorrect, as no pulse can be felt there. The posterior tibial pulse can be felt posteriorly and inferiorly to the medial malleolus, but it should not be assessed first as it is not as distal as the dorsalis pedis pulse.

The anterior tibial artery starts opposite the lower border of the popliteus muscle and ends in front of the ankle, where it continues as the dorsalis pedis artery. As it descends, it runs along the interosseous membrane, the distal part of the tibia, and the front of the ankle joint. The artery passes between the tendons of the extensor digitorum and extensor hallucis longus muscles as it approaches the ankle. The deep peroneal nerve is closely related to the artery, lying anterior to the middle third of the vessel and lateral to it in the lower third.

Torsades de pointes is the most common consequence of Long QT syndrome, which can also result in polymorphic ventricular tachycardia.

Long QT syndrome (LQTS) is a genetic condition that causes a delay in the ventricles’ repolarization. This delay can lead to ventricular tachycardia/torsade de pointes, which can cause sudden death or collapse. The most common types of LQTS are LQT1 and LQT2, which are caused by defects in the alpha subunit of the slow delayed rectifier potassium channel. A normal corrected QT interval is less than 430 ms in males and 450 ms in females.

There are various causes of a prolonged QT interval, including congenital factors, drugs, and other conditions. Congenital factors include Jervell-Lange-Nielsen syndrome and Romano-Ward syndrome. Drugs that can cause a prolonged QT interval include amiodarone, sotalol, tricyclic antidepressants, and selective serotonin reuptake inhibitors. Other factors that can cause a prolonged QT interval include electrolyte imbalances, acute myocardial infarction, myocarditis, hypothermia, and subarachnoid hemorrhage.

LQTS may be detected on a routine ECG or through family screening. Long QT1 is usually associated with exertional syncope, while Long QT2 is often associated with syncope following emotional stress, exercise, or auditory stimuli. Long QT3 events often occur at night or at rest and can lead to sudden cardiac death.

Management of LQTS involves avoiding drugs that prolong the QT interval and other precipitants if appropriate. Beta-blockers are often used, and implantable cardioverter defibrillators may be necessary in high-risk cases. It is important to note that sotalol may exacerbate LQTS.

There is no indication of trauma in patients with advanced renal failure prior to dialysis initiation.

ECG results do not indicate a recent heart attack.

The patient’s age decreases the likelihood of malignancy.

Acute Pericarditis: Causes, Features, Investigations, and Management

Acute pericarditis is a possible diagnosis for patients presenting with chest pain. The condition is characterized by chest pain, which may be pleuritic and relieved by sitting forwards. Other symptoms include non-productive cough, dyspnoea, and flu-like symptoms. Tachypnoea and tachycardia may also be present, along with a pericardial rub.

The causes of acute pericarditis include viral infections, tuberculosis, uraemia, trauma, post-myocardial infarction, Dressler’s syndrome, connective tissue disease, hypothyroidism, and malignancy.

Investigations for acute pericarditis include ECG changes, which are often global/widespread, as opposed to the ‘territories’ seen in ischaemic events. The ECG may show ‘saddle-shaped’ ST elevation and PR depression, which is the most specific ECG marker for pericarditis. All patients with suspected acute pericarditis should have transthoracic echocardiography.

Management of acute pericarditis involves treating the underlying cause. A combination of NSAIDs and colchicine is now generally used as first-line treatment for patients with acute idiopathic or viral pericarditis.

In summary, acute pericarditis is a possible diagnosis for patients presenting with chest pain. The condition is characterized by chest pain, which may be pleuritic and relieved by sitting forwards, along with other symptoms. The causes of acute pericarditis are varied, and investigations include ECG changes and transthoracic echocardiography. Management involves treating the underlying cause and using a combination of NSAIDs and colchicine as first-line treatment.

The branches of the subclavian artery can be remembered using the mnemonic VIT C & D, which stands for Vertebral artery, Internal thoracic, Thyrocervical trunk, Costalcervical trunk, and Dorsal scapular. It is important to note that the Superior thyroid artery is actually a branch of the external carotid artery.

The Subclavian Artery: Origin, Path, and Branches

The subclavian artery is a major blood vessel that supplies blood to the upper extremities, neck, and head. It has two branches, the left and right subclavian arteries, which arise from different sources. The left subclavian artery originates directly from the arch of the aorta, while the right subclavian artery arises from the brachiocephalic artery (trunk) when it bifurcates into the subclavian and the right common carotid artery.

From its origin, the subclavian artery travels laterally, passing between the anterior and middle scalene muscles, deep to scalenus anterior and anterior to scalenus medius. As it crosses the lateral border of the first rib, it becomes the axillary artery and is superficial within the subclavian triangle.

The subclavian artery has several branches that supply blood to different parts of the body. These branches include the vertebral artery, which supplies blood to the brain and spinal cord, the internal thoracic artery, which supplies blood to the chest wall and breast tissue, the thyrocervical trunk, which supplies blood to the thyroid gland and neck muscles, the costocervical trunk, which supplies blood to the neck and upper back muscles, and the dorsal scapular artery, which supplies blood to the muscles of the shoulder blade.

In summary, the subclavian artery is an important blood vessel that plays a crucial role in supplying blood to the upper extremities, neck, and head. Its branches provide blood to various parts of the body, ensuring proper functioning and health.

Infective endocarditis is most frequently caused by Streptococci viridans, which is commonly found in the oral cavity. This type of infection is often linked to patients with inadequate dental hygiene or those who have undergone dental procedures.

Aetiology of Infective Endocarditis

Infective endocarditis is a condition that affects patients with previously normal valves, rheumatic valve disease, prosthetic valves, congenital heart defects, intravenous drug users, and those who have recently undergone piercings. The strongest risk factor for developing infective endocarditis is a previous episode of the condition. The mitral valve is the most commonly affected valve.

The most common cause of infective endocarditis is Staphylococcus aureus, particularly in acute presentations and intravenous drug users. Historically, Streptococcus viridans was the most common cause, but this is no longer the case except in developing countries. Coagulase-negative Staphylococci such as Staphylococcus epidermidis are commonly found in indwelling lines and are the most common cause of endocarditis in patients following prosthetic valve surgery. Streptococcus bovis is associated with colorectal cancer, with the subtype Streptococcus gallolyticus being most linked to the condition.

Culture negative causes of infective endocarditis include prior antibiotic therapy, Coxiella burnetii, Bartonella, Brucella, and HACEK organisms (Haemophilus, Actinobacillus, Cardiobacterium, Eikenella, Kingella). It is important to note that systemic lupus erythematosus and malignancy, specifically marantic endocarditis, can also cause non-infective endocarditis.

Understanding Warfarin: Mechanism of Action, Indications, Monitoring, Factors, and Side-Effects

Warfarin is an oral anticoagulant that has been widely used for many years to manage venous thromboembolism and reduce stroke risk in patients with atrial fibrillation. However, it has been largely replaced by direct oral anticoagulants (DOACs) due to their ease of use and lack of need for monitoring. Warfarin works by inhibiting epoxide reductase, which prevents the reduction of vitamin K to its active hydroquinone form. This, in turn, affects the carboxylation of clotting factor II, VII, IX, and X, as well as protein C.

Warfarin is indicated for patients with mechanical heart valves, with the target INR depending on the valve type and location. Mitral valves generally require a higher INR than aortic valves. It is also used as a second-line treatment after DOACs for venous thromboembolism and atrial fibrillation, with target INRs of 2.5 and 3.5 for recurrent cases. Patients taking warfarin are monitored using the INR, which may take several days to achieve a stable level. Loading regimes and computer software are often used to adjust the dose.

Factors that may potentiate warfarin include liver disease, P450 enzyme inhibitors, cranberry juice, drugs that displace warfarin from plasma albumin, and NSAIDs that inhibit platelet function. Warfarin may cause side-effects such as haemorrhage, teratogenic effects, skin necrosis, temporary procoagulant state, thrombosis, and purple toes.

In summary, understanding the mechanism of action, indications, monitoring, factors, and side-effects of warfarin is crucial for its safe and effective use in patients. While it has been largely replaced by DOACs, warfarin remains an important treatment option for certain patients.

The filling of the coronary arteries takes place during ventricular diastole and not during ventricular systole, which is when isovolumetric contraction occurs.

Understanding Coronary Circulation

Coronary circulation refers to the blood flow that supplies the heart with oxygen and nutrients. The arterial supply of the heart is divided into two main branches: the left coronary artery (LCA) and the right coronary artery (RCA). The LCA originates from the left aortic sinus, while the RCA originates from the right aortic sinus. The LCA further divides into two branches, the left anterior descending (LAD) and the circumflex artery, while the RCA supplies the posterior descending artery.

The LCA supplies the left ventricle, left atrium, and interventricular septum, while the RCA supplies the right ventricle and the inferior wall of the left ventricle. The SA node, which is responsible for initiating the heartbeat, is supplied by the RCA in 60% of individuals, while the AV node, which is responsible for regulating the heartbeat, is supplied by the RCA in 90% of individuals.

On the other hand, the venous drainage of the heart is through the coronary sinus, which drains into the right atrium. During diastole, the coronary arteries fill with blood, allowing for the delivery of oxygen and nutrients to the heart muscles. Understanding the coronary circulation is crucial in the diagnosis and management of various heart diseases.

Furosemide is a medication that is often prescribed to patients with heart failure who have excess fluid in their bodies. It works by inhibiting the Na-K-Cl cotransporter in the thick ascending limb of the loop of Henle, which prevents the reabsorption of sodium. This results in a less hypertonic renal medulla and reduces the osmotic force that causes water to be reabsorbed from the collecting ducts. As a result, more water is excreted through the kidneys.

It is important to be aware of the common side effects of loop diuretics, which are listed in the notes below.

Loop Diuretics: Mechanism of Action and Clinical Applications

Loop diuretics, such as furosemide and bumetanide, are medications that inhibit the Na-K-Cl cotransporter (NKCC) in the thick ascending limb of the loop of Henle. By doing so, they reduce the absorption of NaCl, resulting in increased urine output. Loop diuretics act on NKCC2, which is more prevalent in the kidneys. These medications work on the apical membrane and must first be filtered into the tubules by the glomerulus before they can have an effect. Patients with poor renal function may require higher doses to ensure sufficient concentration in the tubules.

Loop diuretics are commonly used in the treatment of heart failure, both acutely (usually intravenously) and chronically (usually orally). They are also indicated for resistant hypertension, particularly in patients with renal impairment. However, loop diuretics can cause adverse effects such as hypotension, hyponatremia, hypokalemia, hypomagnesemia, hypochloremic alkalosis, ototoxicity, hypocalcemia, renal impairment, hyperglycemia (less common than with thiazides), and gout. Therefore, careful monitoring of electrolyte levels and renal function is necessary when using loop diuretics.

The atrioventricular node is most likely supplied by the right coronary artery.

The left coronary artery gives rise to the left anterior descending and circumflex arteries.

An anterior myocardial infarction is caused by occlusion of the left anterior descending artery.

The coronary sinus is a venous structure that drains blood from the heart and returns it to the right atrium.

Understanding Coronary Circulation

Coronary circulation refers to the blood flow that supplies the heart with oxygen and nutrients. The arterial supply of the heart is divided into two main branches: the left coronary artery (LCA) and the right coronary artery (RCA). The LCA originates from the left aortic sinus, while the RCA originates from the right aortic sinus. The LCA further divides into two branches, the left anterior descending (LAD) and the circumflex artery, while the RCA supplies the posterior descending artery.

The LCA supplies the left ventricle, left atrium, and interventricular septum, while the RCA supplies the right ventricle and the inferior wall of the left ventricle. The SA node, which is responsible for initiating the heartbeat, is supplied by the RCA in 60% of individuals, while the AV node, which is responsible for regulating the heartbeat, is supplied by the RCA in 90% of individuals.

On the other hand, the venous drainage of the heart is through the coronary sinus, which drains into the right atrium. During diastole, the coronary arteries fill with blood, allowing for the delivery of oxygen and nutrients to the heart muscles. Understanding the coronary circulation is crucial in the diagnosis and management of various heart diseases.

As a result of the volume overload caused by heart failure, she will have a higher susceptibility to chest infections due to pulmonary edema and leg infections due to peripheral edema.

Chronic heart failure can be managed through drug treatment, according to updated guidelines issued by NICE in 2018. While loop diuretics are useful in managing fluid overload, they do not reduce mortality in the long term. The first-line treatment for all patients is a combination of an ACE-inhibitor and a beta-blocker, with clinical judgement used to determine which one to start first. Aldosterone antagonists are recommended as second-line treatment, but potassium levels should be monitored as both ACE inhibitors and aldosterone antagonists can cause hyperkalaemia. Third-line treatment should be initiated by a specialist and may include ivabradine, sacubitril-valsartan, hydralazine in combination with nitrate, digoxin, and cardiac resynchronisation therapy. Other treatments include annual influenzae and one-off pneumococcal vaccines. Those with asplenia, splenic dysfunction, or chronic kidney disease may require a booster every 5 years.